AFP and neoplasm: Age ≤50 yr, not having received radical treatment after initial TACE, maximum tumor diameter ≥10 cm, the presence of extrahepatic metastasis before initial TACE, the presence of portal/hepatic vein tumor thrombosis before initial TACE, AFP >400 ng/ml, PLT >100×109/L, AST >45 U/L, ALB <35 g/L, stage B/C/D according to the BCLC staging system, lipiodol dose during TACE >15 ml, and tumor response that were evaluated as PD and SD after initial TACE and found to be statistically significant by univariate analysis were included in a multivariate regression analysis.